Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Male Infertility Market Forecast to 2027 - COVID-19 Impact and Analysis -

November 18, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Nov 18, 2020--

The “Male Infertility Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Test; Treatment Type; Distribution Channel; End User, and Geography” report has been added to’s offering.


According to this report the market is expected to reach US $6,213.96 million by 2027 from US $3,883.82 million in 2019; it is estimated to grow at a CAGR of 6.2% from 2020 to 2027.

The report highlights the trends prevailing in the global male infertility market, and the drivers and deterrents pertaining to its growth. The growth of the male infertility market is attributed to the increase in male infertility worldwide and technological advancements. However, high cost of procedures hampers the growth of the market.

The male infertility market, by test, is segmented into DNA fragmentation technique, oxidative stress analysis, computer assisted semen analysis, microscopic examination, sperm agglutination, sperm penetration assay, and others. The DNA fragmentation technique segment held the largest share of the market in 2019, whereas the computer assisted semen analysis segment is anticipated to register the highest CAGR of 7.2% in the market during the forecast period.

The growing adoption of advanced and improved assisted reproductive technologies, and rise in infertility ratio among males are among the factors augmenting the growth of the male infertility market for the DNA fragmentation technique. Further the rise in the market for computer-assisted semen analysis can be attributed to the growing emphasis of various manufacturers on offering innovative products. For instance, in June 2017, MICROPTIC collaborated with Embryotools for to develop a sperm analysis system in their lab and conduct training for the operations of the same.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the male infertility market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global male infertility market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.


Market Dynamics


  • Increase in Male Infertility Worldwide
  • Technological Advancements


  • High Cost of Procedures
  • Opportunity
  • Conduction of Awareness Campaigns

Future Trend

  • Adoption of Assisted Reproductive Technologies (ART)

Companies Mentioned

  • Sanofi
  • Bayer AG
  • Endo Pharmaceuticals Inc.
  • SCSA Diagnostics, Inc.
  • Andrology Solutions
  • Halotech DNA
  • Intas Pharmaceuticals Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Vitrolife

For more information about this report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 11/18/2020 11:07 AM/DISC: 11/18/2020 11:07 AM